TG Therapeutics, Inc.
NASDAQ:TGTX
Overview | Financials
| Company Name | TG Therapeutics, Inc. |
| Symbol | TGTX |
| Currency | USD |
| Price | 32.38 |
| Market Cap | 5,137,605,080 |
| Dividend Yield | 0% |
| 52-week-range | 21.16 - 46.48 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Michael S. Weiss Esq. |
| Website | https://www.tgtherapeutics.com |
An error occurred while fetching data.
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







